Amir J Guri Selected Research

Abscisic Acid

9/2011	T cell PPARγ is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD.
1/2011	Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma.
1/2011	Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists.
12/2010	Abscisic acid ameliorates atherosclerosis by suppressing macrophage and CD4+ T cell recruitment into the aortic wall.
12/2010	Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration.
10/2010	Abscisic acid synergizes with rosiglitazone to improve glucose tolerance and down-modulate macrophage accumulation in adipose tissue: possible action of the cAMP/PKA/PPAR γ axis.
4/2008	Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue.
2/2007	Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Amir J Guri Research Topics

Disease

11	Inflammation (Inflammations) 09/2011 - 02/2007
8	Obesity 01/2012 - 12/2006
4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2011 - 03/2010
4	Insulin Resistance 12/2010 - 02/2007
3	Weight Gain 01/2012 - 10/2010
2	Hypertrophy 01/2008 - 02/2007
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2008 - 12/2006
1	Heart Failure 01/2011
1	Metabolic Diseases (Metabolic Disease) 01/2011
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2010
1	Hypertension (High Blood Pressure) 12/2010
1	Atherosclerosis 12/2010
1	Body Weight (Weight, Body) 06/2010
1	Weight Loss (Weight Reduction) 04/2010
1	Colorectal Neoplasms (Colorectal Cancer) 03/2010
1	Adenocarcinoma 03/2010
1	Colitis 03/2010
1	Neoplasms (Cancer) 03/2010
1	Chronic Disease (Chronic Diseases) 01/2008

Drug/Important Bio-Agent (IBA)

8	Abscisic AcidIBA 09/2011 - 02/2007
7	PPAR gammaIBA 01/2011 - 02/2007
7	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2011 - 12/2006
3	Glucose (Dextrose)FDA LinkGeneric 01/2012 - 02/2007
3	Plant Growth Regulators (Plant Hormones)IBA 09/2011 - 04/2008
2	LigandsIBA 01/2011 - 12/2006
2	Rosiglitazone (Avandia)FDA Link 01/2011 - 10/2010
2	Insulin (Novolin)FDA Link 10/2010 - 04/2008
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 06/2010 - 04/2010
1	Hormones (Hormone)IBA 01/2012
1	LeptinIBA 01/2012
1	Blood Glucose (Blood Sugar)IBA 01/2012
1	eleostearic acidIBA 01/2011
1	punicic acidIBA 01/2011
1	catalpic acidIBA 01/2011
1	Apolipoproteins E (ApoE)IBA 12/2010
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 10/2010
1	AzoxymethaneIBA 03/2010
1	Conjugated Linoleic AcidsIBA 03/2010
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 03/2010
1	Dextrans (Dextran)FDA Link 03/2010
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 04/2008
1	LipidsIBA 01/2008
1	ThiazolidinedionesIBA 02/2007
1	Messenger RNA (mRNA)IBA 02/2007
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2007
1	Nonesterified Fatty Acids (NEFA)IBA 12/2006